(51) International Patent Classification 5 :		(11) International Publication Number:	**WO 92/15694**
C12N 15/85, 5/16, C07H 15/12	**A1**	(43) International Publication Date:	17 September 1992 (17.09.92)

(21) International Application Number: PCT/US92/01899

(22) International Filing Date: 6 March 1992 (06.03.92)

(30) Priority data:
666,252   8 March 1991 (08.03.91)   US

(71) Applicant: THE SALK INSTITUTE FOR BIOLOGICAL STUDIES [US/US]; 10010 North Torrey Pines Road, La Jolla, CA 92037 (US).

(72) Inventors: WAHL, Geoffrey, M. ; 4258 Arguello Street, San Diego, CA 92103 (US). O'GORMAN, Stephen, V. ; 2761 Havasupai Avenue, San Diego, CA 92117 (US).

(74) Agents: CAMPBELL, Cathryn et al.; Pretty, Schroeder, Brueggemann & Clark, 444 South Flower Street, Suite 2000, Los Angeles, CA 90071 (US).

(81) Designated States: AT (European patent), BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), MC (European patent), NL (European patent), SE (European patent).

Published
With international search report.

(54) Title: FLP-MEDIATED GENE MODIFICATION IN MAMMALIAN CELLS, AND COMPOSITIONS AND CELLS USEFUL THEREFOR

(57) Abstract

A gene activation/inactivation and site-specific integration system has been developed for mammalian cells. The invention system is based on the recombination of transfected sequences by FLP, a recombinase derived from Saccharomyces. In several cell lines, FLP has been shown to rapidly and precisely recombine copies of its specific target sequence. For example, a chromosomally integrated, silent β-galactosidase reporter gene was activated for expression by FLP-mediated removal of intervening sequences to generate clones of marked cells. Alternatively, the reverse reaction can be used to target transfected DNA to specific chromosomal sites. These results demonstrate that FLP can be used, for example, to mosaically activate or inactivate transgenes for a variety of therapeutic purposes, as well as for analysis of vertebrate development.

FLP-MEDIATED GENE MODIFICATION IN MAMMALIAN CELLS, AND COMPOSITIONS AND CELLS USEFUL THEREFOR

This invention relates to recombinant DNA technology. In a particular aspect, this invention relates to methods for the site-specific recombination of DNA in mammalian cells or host mammalian organisms. In

5   another aspect, the present invention relates to novel DNA constructs, as well as compositions, cells and host organisms containing such constructs. In yet another aspect, the present invention relates to methods for the activation and/or inactivation of expression of

10   functional genes. In a further aspect, the present invention relates to methods for the introduction of DNA into specific sites in the genome of mammalian cells. In a still further aspect, the present invention relates to gene therapy methods. In still another aspect, the

15   present invention relates to means for the recovery of transfected DNA from a cell or host organism. In a still further aspect, the present invention relates to assay methods.

20

BACKGROUND OF THE INVENTION

Many recent manipulations of gene expression involve the introduction of transfected genes

25   (transgenes) to confer some novel property upon, or to alter some intrinsic property of, mammalian cells or organisms. The efficacy of such manipulations is often impaired by such problems as the inability to control the chromosomal site of transgene integration; or the

30   inability to control the number of copies of a transgene that integrate at the desired chromosomal site; or by difficulties in controlling the level, temporal characteristics, or tissue distribution of transgene

-2-

expression; or by the difficulty of modifying the
structure of transgenes once they are integrated into
mammalian chromosomes.

Transgenes are often introduced into
5   mammalian cells or organisms to determine which
components of a transgene are required for specific
qualitative or quantitative alterations of the host
system. Since both chromosomal position and copy number
are major determinants of transgene function, the
10 usefulness of these analyses is limited because current
techniques for efficiently introducing transgenes into
mammalian hosts result in the insertion of a variable
number of transgene copies at random chromosomal
positions. It is, therefore, difficult (if not
15 impossible) to compare the effects of one transgene to
those of another if the two transgenes occupy different
chromosomal positions and are present in the genome at
different copy numbers. Considerably more refined
analyses would be possible if one could routinely
20 introduce single copies of a variety of transgenes into a
defined chromosomal position.

The spatial or temporal characteristics of
transgene expression is difficult to control in intact
organisms. The restricted expression of transgenes is
25 potentially of great interest, as this technique can be
employed for a variety of therapeutic applications, e.g.,
for the selective interruption of a defective gene, for
the alteration of expression of a gene which is otherwise
over-expressed or under-expressed, for the selective
30 introduction of a gene whose product is desirable in the
host, for the selective removal or disruption of a gene
whose expression is no longer desired in the host, and
the like.

Transgene expression is typically governed
35 by a single set of control sequences, including promoters
and enhancers which are physically linked to the

transgenes (i.e., cis-acting sequences). Considerably
greater expression control could be achieved if transgene
expression could be placed under the binary control of
these cis-acting sequences, plus an additional set of
5   sequences that were not physically linked to the
transgenes (i.e., trans-acting sequences). A further
advantage would be realized if the transient activity of
these trans-acting functions resulted in a stable
alteration in transgene expression. In this manner, it
10 would be possible, for example, to introduce into a host
a transgene whose expression would have lethal or
deleterious effects if it was constitutively expressed in
all cells. This would be accomplished by delaying the
expression of the transgene to a specific time or
15 developmental stage of interest, or by restricting the
expression of the transgene to a specific subset of the
cell population.

It is currently difficult (if not
impossible) to precisely modify the structure of
20 transgenes once they have been introduced into mammalian
cells. In many applications of transgene technology, it
would be desirable to introduce the transgene in one
form, and to then be able to modify the transgene in a
defined manner. By this means, transgenes could be
25 activated or inactivated or the sequences which control
transgene expression could be altered by either removing
sequences present in the original transgene or by
inserting additional sequences into the transgene.

Previous descriptions of recombinase-
30 mediated rearrangement of chromosomal sequences in
Drosophila and mammalian cells have not directly
addressed the question of whether site-specific
recombinases could routinely create a functional
translational reading frame. Moreover, the reported
35 efficiency of the prior art recombinase system, in the
only other description of site-specific recombination in

-4-

mammalian cells reported to date [based on Cre
recombinase, described by Sauer and Henderson in <u>Nucleic
Acids Research</u>, Vol. 17: 147 (1989)] appears to be quite
low.

5

BRIEF DESCRIPTION OF THE INVENTION

10   In accordance with the present invention,
we have developed a system for the selective modification
of chromosomal or extrachromosomal DNA in mammalian
cells. Selective modification can involve the insertion
of one DNA into another DNA (e.g., to create a hybrid
gene, to activate a gene, to inactivate a gene, and the
15 like), or the removal of specific DNA molecule(s) from
other DNA molecule(s) containing the DNA to be removed
(e.g., to inactivate a gene, to bring desired DNA
fragments into association with one another, and the
like).
20   The recombination system of the present
invention is based on site-specific recombinase, FLP. In
one application of the invention recombination system,
FLP-mediated removal of intervening sequences is required
for the formation of a functional gene. Expression of
25 the functional gene therefore, falls under the control of
both the regulatory sequences associated with the
functional gene and also under the control of those
sequences which direct FLP expression.
        The reverse of the above-described
30 process, i.e., the FLP-mediated introduction of DNA,
provides a convenient and selective means to introduce
DNA into specific sites in mammalian chromosomes.
        FLP-mediated recombination of marker genes
provides a means to follow the fate of various sequences
35 over the course of development and/or from generation-to-
generation. The recombination event creates a functional

-5-

marker gene. This gain-of-function system can be used
for lineage analyses in a wide variety of tissues in
different organisms. Prior to FLP-mediated
recombination, the marker gene is normally silent, i.e.,
5   the phenotype typical of the marker is not observed. In
the absence of FLP, spontaneous recombination to produce
functional marker occurs only at very low frequencies.
In the presence of FLP, functional marker is efficiently
produced. In addition, this gain-of-function system is
10 heritable and is easily detected by simple histochemical
assays. For example, in transgenic mice, the lineages in
which recombination is to occur can be controlled by
appropriate selection of the promoters used to drive FLP
expression. This could include promoters that are only
15 transiently active at a developmental stage that
substantially precedes overt cell differentiation. Since
transcription of the marker gene is controlled by
regulatory sequences associated therewith, functional
marker genes can be expressed at later developmental
20 stages, after cell differentiation has occurred. By this
means, it is possible to construct a map for mammalian
development that correlates embryonic patterns of gene
expression with the organization of mature tissues.

25
                 BRIEF DESCRIPTION OF THE FIGURES

                  Figure 1 presents schematic diagrams of
FLP-mediated recombination events. In Figure 1A, FLP-
30 mediated introduction of DNA is illustrated, while in
Figure 1B, FLP-mediated removal of intervening sequences
is illustrated.
                  Figure 2 is presented in three parts.
Figure 2A presents schematic diagrams of the expression
35 vectors pFRTβGAL, pNEOβGAL, and pOG44 FLP. Figure 2B
presents a Southern blot of Hirt lysates prepared from

-6-

293 (human embryonic kidney) cells transfected with one
microgram of pNEOβGAL and varying amounts of the pOG44
FLP expression vector. Figure 2C graphically presents
the β-galactosidase activities in the same transfections
5   shown in part B, referred to above.

Figure 3A, at the top, presents a
schematic of the pattern of plasmid integration in E25
deduced from Southern blot analysis. Figure 3A, in the
middle, presents the predicted pattern for
10   β-galactosidase positive subclones of E25 if precise
recombination across the FLP-recombination target sites
occurs. Figure 3A, at the bottom, presents the predicted
pattern for β-galactosidase negative, neomycin resistant
subclones of E25B2 after FLP mediated insertion of pOG45.
15   Figure 3B presents an analysis of genomic DNA from a cell
line with a single integrated copy of pNEOβGAL (i.e.,
CVNEOβGAL/E25, designated as E25), two derivative
β-galactosidase-positive subclones (designated as E25B1
and E25B2), and two subclones derived from E25B2 after
20   transfection with pOG45 (designated as B2N1 and B2N2).

DETAILED DESCRIPTION OF THE INVENTION

25   In accordance with the present invention,
there is provided a mammalian recombination system
comprising:

(i)   FLP recombinase, or a nucleotide sequence
encoding same, and
30   (ii) a first DNA comprising a nucleotide
sequence containing at least one FLP
recombination target site.

In accordance with another embodiment of
the present invention, there are provided novel DNA
35   constructs useful for the introduction of DNA into the

-7-

genome of a transfected organism, said DNA construct
comprising, as an autonomous fragment:

> (a) at least one FLP recombination target
>   site,

5

> (b) at least one restriction endonuclease
>   recognition site,

> (c) at least one marker gene,

> (d) a bacterial origin of replication, and
>   optionally

10

> (e) a mammalian cellular or viral origin of
>   DNA replication.

In accordance with yet another embodiment
of the present invention, there are provided novel DNA
constructs useful for the rescue of DNA from the genome

15 of a transfected organism, said DNA construct comprising,
as an autonomous fragment, in the following order,
reading from 5' to 3' along said fragment:

> (a) a first FLP recombination target site,

> (b) an insert portion comprising, in any

20 > suitable sequence:

> > (1) at least one restriction endonuclease
> >   recognition site,

> > (2) at least one marker gene,

> > (3) a bacterial origin of replication,

25 > > and optionally

> > (4) a mammalian cellular or viral origin
> >   of DNA replication, and

> (c) a second FLP recombination target site in
>   tandem with said first FLP recombination

30 >   target site.

In addition, there are provided methods for the recovery
of transfected DNA from the genome of a transfected
organism employing the above-described constructs.

In accordance with still another

35 embodiment of the present invention, there is provided a
method for the assembly of a functional gene (which is

-8-

then suitable for activation of expression), in mammalian
cells, by recombination of individually inactive gene
segments derived from one or more gene(s) of interest,
wherein each of said segments contains at least one
5   recombination target site, said method comprising:

> contacting said individually inactive gene
> segments with a FLP recombinase, under
> conditions suitable for recombination to occur,
> thereby providing a DNA sequence which encodes
10 a functional gene of interest.

In accordance with a further embodiment of
the present invention, there is provided a method for the
disruption of functional gene(s) of interest, thereby
inactivating expression of such gene(s), in mammalian
15 cells, wherein said gene(s) of interest contain at least
one FLP recombination target site, said method comprising
contacting said gene(s) of interest with:

> (i) a DNA segment which contains at least one
> .. FLP recombination target site, and
20 (ii) FLP recombinase;

wherein said contacting is carried out under conditions
suitable for recombination to occur between said gene and
said DNA segment, thereby disrupting the gene(s) of
interest and rendering said gene(s) non-functional.

25   In accordance with a still further
embodiment of the present invention, there is provided a
method for the precisely targeted integration of DNA into
the genome of a host organism, said method comprising:

> (i) introducing a FLP recombination target
30 site into the genome of cells which are
> compatible with the cells of the subject,
> (ii) introducing a first DNA comprising a
> nucleotide sequence containing at least
> one FLP recombination target site therein
35 into the FLP recombination target site in
> the genome of said cells by contacting

-9-

said cells with said first DNA and FLP
recombinase, and thereafter

(iii) introducing the cells produced by the
process of step (ii) into said subject,
5   wherein the resulting cells and/or
organism have the optional ability to
have DNA reproducibly and repetitively
inserted into and/or recovered from the
host cells and/or organism.

10   In accordance with another aspect of the
present invention, there are provided mammalian cells,
wherein the genomic DNA of said cells contain at least
one FLP recombination target site therein.

                    In accordance with yet another aspect of
15 the present invention, there are provided transgenic,
non-human mammals, wherein said mammals contain at least
one FLP recombination target site in the genomic DNA
thereof.

                    In accordance with yet another aspect of
20 the present invention, there is provided a method for the
site-specific integration of transfected DNA into the
genome of the above-described cells and/or transgenic,
non-human mammals, said method comprising:

        (i)   contacting said genome with:
25   (a) FLP recombinase, and
                    (b) a first DNA comprising a
                        nucleotide sequence containing
                        at least one FLP recombination
                        target site therein; and
30   thereafter

        (ii)   maintaining the product of Step (i)
               under conditions suitable for site-
               specific integration of said DNA
               sequence to occur at the FLP
35   recombination target site in said
               genome.

-10-

In accordance with a further aspect of the
present invention, there is provided a method for the
analysis of the development of a mammal, said method
comprising:

5   (a) providing a transgenic mammal comprising:

(i) an expression construct encoding FLP
under the control of a conditional
promoter, and

(ii) a reporter construct under the
10   control of the same or a different
promoter, wherein said reporter
construct encodes a functional or
non-functional reporter gene product,
and wherein said construct contains
15   at least one FLP recombination target
site therein,

wherein the functional
expression of the functional reporter
gene is disrupted when said FLP
20   recombination event occurs, or

wherein the functional
expression of the non-functional
reporter gene commences when said FLP
recombination event occurs; and

25   (b) following the development of said mammal to
determine when expression of functional reporter gene
product either commences or is disrupted.

In accordance with a still further aspect
of the present invention, there is provided a co-
30 transfection assay FLP-mediated recombination, said assay
comprising:

(a) co-transfecting a host mammalian cell with:

(i) a FLP expression plasmid, and

(ii) a reporter plasmid comprising a
35   reporter gene inactivated by the presence

-11-

of at least one recombination target site;
and

(b) monitoring said host cell under a variety
of conditions for the gain of expression of functional
5 reporter gene product.

FLP recombinase is a protein which
catalyzes a site-specific recombination reaction that is
involved in amplifying the copy number of the 2μ plasmid
of S.cerevisiae during DNA replication. FLP protein has
10 been cloned and expressed in E.coli [see, for example,
Cox, in proceedings of the National Academy of Sciences
U.S.A., Vol. 80: 4223-4227 (1983)], and has been purified
to near homogeneity [see, for example, Meyer-Lean, et
al., in Nucleic Acids Research, Vol. 15: 6469-6488
15 (1987)]. FLP recombinases contemplated for use in the
practice of the present invention are derived from
species of the genus Saccharomyces. Preferred
recombinases employed in the practice of the present
invention are derived from strains of Saccharomyces
20 cerevisiae. Especially preferred recombinases employed
in the practice of the present invention are proteins
having substantially the same amino acid sequence as set
forth in Sequence I.D. No. 2, as encoded, for example, by
Sequence I.D. No. 1, or the sequence set forth by Hartley
25 and Donelson, Nature 286: 860 (1980).

The FLP recombination target site
(sometimes referred to herein as "FRT") has also been
identified as minimally comprising two 13 base-pair
repeats, separated by an 8 base-pair spacer, as follows:

30

-Spacer-
5'-GAAGTTCCTATTC[TCTAGAAA]GTATAGGAACTTC-3'
XbaI
site

35

The nucleotides in the above "spacer" region can be
replaced with any other combination of nucleotides, so

-12-

long as the two 13 base-pair repeats are separated by 8
nucleotides. The actual nucleotide sequence of the
spacer is not critical, although those of skill in the
art recognize that, for some applications, it is
5   desirable for the spacer to be asymmetric, while for
other applications, a symmetrical spacer can be employed.
Generally, the spacers of the FLP recombination target
sites undergoing recombination with one another will be
the same.

10   As schematically illustrated in Figure 1A,
contact of genomic DNA containing a FLP recombination
target site (shown as the linear Psv-BETA-GAL construct)
with a vector containing a FLP recombination target site,
in the presence of the protein, FLP recombinase, results
15   in recombination that forms a new genomic sequence
wherein the vector sequences have been precisely
incorporated into the genome of the host. The reverse of
this process is shown schematically in Figure 1B, wherein
a genomic sequence or construct containing two tandemly
20   oriented FLP recombination target sites, upon contacting
with FLP, is recombined and the FLP recombination target
site-bounded fragment is excised as a circular molecule.
               Genes of interest contemplated for use in
the practice of the present invention can be selected
25   from genes which provide a readily analyzable functional
feature to the host cell and/or organism, e.g., visible
markers (such as β-galactosidase, thymidine kinase,
tyrosinase, and the like), selectable markers, (such as
markers useful for positive and negative selection, e.g.,
30   genes for antibiotic resistance), as well as other
functions which alter the phenotype of the recipient
cells, and the like.
               The first DNA employed in the practice of
the present invention can comprise any nucleotide
35   sequence containing at least one FLP recombination target
site, which will precisely define the locus at which FLP-

-13-

mediated recombination will occur. The nucleotide
sequence can comprise all or part of a gene of interest,
as well as other sequences not necessarily associated
with any known gene. Optionally, for ease of later
5   recovery of the gene of interest (in "activated" or
modified form), the first DNA can optionally contain a
second FLP recombination target site.

         The second DNA employed in the practice of
the present invention is selected from at least a second
10 portion of the first gene of interest or at least a
portion of a second gene of interest (including an intact
form of a second gene of interest). When the second DNA
is at least a second portion of the first gene of
interest, the site-specific recombination of the present
15 invention may act to provide a functional combination of
the different portions of the first gene of interest.
Alternatively, when the second DNA is at least a portion
of a second gene of interest, the site-specific
recombination of the present invention may act to provide
20 a functional hybrid gene, which produces a product which
is not identical with either the product of the first
gene or the second gene. As yet another alternative,
when the second DNA is a portion of a second gene, the
site-specific recombination of the present invention may
25 act to disrupt the function of the first gene of
interest. Based on the nature of the first DNA and the
second DNA, as well as the mode of interaction between
the two, the site-specific interaction of the present
invention may create or disrupt a feature which is
30 colorimetrically detectable, immunologically detectable,
genetically detectable, and the like.

         In accordance with the present invention,
assembly of a functional expression unit is achieved in
any of a variety of ways, e.g., by association of the
35 gene of interest with a functional promoter, by assembly
of common gene fragments to produce a complete functional

-14-

gene (which, in combination with its promoter, comprises
a functional expression unit), or assembly of diverse
gene fragments from diverse sources to produce a
functional, hybrid gene (which, in combination with a
5   promoter, comprises a functional expression unit), and
the like. Upon assembly of a functional expression unit
as described herein, expression of the functional gene to
produce a protein product can be activated in the usual
manner. In the absence of FLP-mediated recombination,
10   activation of expression would fail to produce a
functional protein product.

               In accordance with the present invention,
dis-assembly of a functional expression unit is achieved
in any of a variety of ways, e.g., by dis-associating the
15   gene of interest from a functional promoter, by dis-
assembly (e.g., disruption) of the functional gene (e.g.,
by introduction of DNA which renders the entire sequence
non-functional), by removal of a substantial portion of
the coding region of said gene, and the like. Upon dis-
20   assembly of a functional expression unit as described
herein, expression of the functional gene product under
the conditions required prior to gene dis-assembly is no
longer possible. The ability of the expression unit to
be activated for expression has therefore been disrupted.
25   The gene in this situation can be said to be inactivated,
since activation of expression is not possible.

               Individually inactive gene segments
contemplated for use in the practice of the present
invention are fragments which, alone, do not encode
30   functional products. Such fragments can be derived from
a first gene of interest alone, or from both a first and
second gene of interest DNA fragments.

               When gene inactivation is desired, the
gene of interest can be disrupted with a DNA fragment
35   which throws the gene of interest out of reading frame
(e.g., an insert wherein the number of nucleotides is not

-15-

a multiple of 3). Alternatively, the gene of interest
can be disrupted with a fragment which encodes a segment
which is substantially dissimilar with the gene of
interest so as to render the resulting product non-
5 functional. As yet another alternative, the gene of
interest can be disrupted so as to dis-associate the gene
of interest from the transcriptional control of the
promoter with which it is normally associated.

           The introduction of DNA, e.g., DNA
10 encoding FLP recombination target sites, into the genome
of target cells can be accomplished employing standard
techniques, e.g., transfection, microinjection,
electroporation, infection with retroviral vectors, and
the like.

15   Introduction of protein, e.g., FLP
recombinase protein, to host cells and/or organisms can
be accomplished by standard techniques, such as for
example, injection or microinjection, transfection with
nucleotide sequences encoding FLP, and the like.

20   When employed for gene therapy of an
intact organism, introduction of transgenic cells into
the subject is accomplished by standard techniques, such
as for example, grafting, implantation, and the like.

           Mammalian cells contemplated for use in
25 the practice of the present invention include all members
of the order Mammalia, such as, for example, human cells,
mouse cells, rat cells, monkey cells, hamster cells, and
the like.

           Host organisms contemplated for use in the
30 practice of the present invention include each of the
organism types mentioned above, with the proviso,
however, that no claim is made to genetically modified
human hosts (although the present invention contemplates
methods for the treatment of humans).

35   Once FLP recombinase (or DNA encoding
same) and DNA containing at least one FLP recombination

-16-

target site have been introduced into suitable host
cells/organisms, the cells/host organisms are maintained
under conditions suitable for the site-specific
recombination of DNA. Such conditions generally involve
5   conditions required for the viability of the host cell or
organism. For in vitro manipulations, conditions
employed typically involve low concentrations of a
variety of buffers having a pH of between about 5-9 and
ionic strengths in the range of about 50-350 mM. See,
10   for example, Senecoff, et al., in *Journal of Molecular
Biology*, Vol. 201: 405-421 (1988).

In accordance with a particular aspect of
the present invention, a co-transfection assay has been
developed which can be used to characterize FLP-mediated
15   recombination of extrachromosomal DNA in a variety of
cell lines. Cells are co-transfected with an expression
construct and a "reporter" plasmid that is a substrate
for the recombinase. The expression construct encodes a
FLP recombinase protein. The reporter plasmid encodes
20   either a functional reporter gene containing at least one
recombination target site therein, or a non-functional
reporter gene containing at least one recombination
target site therein. Upon expression of FLP by the
expression construct, the functional reporter gene will
25   be rendered non-functional, or the non-functional
reporter gene will be rendered functional. Thus, the
activity of the expression construct can be assayed
either by recovering the reporter plasmid and looking for
evidence of recombination at the DNA level, or by
30   preparing cytoplasmic extracts and looking for evidence
of recombination at the protein level (i.e., by
measuring the expression of reporter gene activity
generated by the recombined reporter). Such assays are
described in greater detail in Example 1 below.

-17-

The invention will now be described in
greater detail by reference to the following non-limiting
examples.

5   EXAMPLES

Example 1
Co-transfection Assays

10   The co-transfection assay used to
characterize FLP-mediated recombination of
extrachromosomal DNA involved transfection of cells with
an expression construct and a "reporter" plasmid that was
a substrate for the recombinase. The activity of the
15 expression construct could be assayed either by
recovering the reporter plasmid and looking for molecular
evidence of recombination at the DNA level, or by
preparing cytoplasmic extracts and looking for evidence
of recombination at the protein level (i.e., by measuring
20 β-galactosidase activity generated by recombined
reporter).

The pNEOβGAL reporter plasmid used for
these assays was derived from pFRTβGAL (Fig. 2A). In the
Figure, half-arrows indicate positions of FLP
25 recombination target (FRT) sites; E and S designate EcoRI
and ScaI restriction sites, respectively; Psv designates
early promoter from SV40; BETA-GAL designates the β-
galactosidase structural sequence; NEO designates
neomycin expression cassette; Pcmv designates the
30 cytomegalovirus immediate early promoter; IN designates
an intron; FLP designates a FLP coding sequence; AN
designates an SV40 adenylation cassette; thin lines
represent vector sequences; and the sizes of restriction
fragments are indicated in kb.
35   pFRTβGAL contains a version of the
bacterial β-galactosidase sequence modified by insertion

-18-

of a FLP recombination target site, or FRT, within the
protein coding sequence immediately 3' to the
translational start. The oligonucleotide used for the
construction of pFTβRGAL was:

5

    5'-GATCCCGGGCTACCATGGA·GAAGTTCCTATTC·CGAAGTTCCTATTC
               (TCTAGA)AAGTATAGGAACTTCA-3'.

This oligonucleotide contains an in-frame start codon,
10 minimal FRT site, and an additional copy of the 13-bp FRT
repeat [·XXX·]; the XbaI site within the FRT spacer is
enclosed in parentheses. The linker was inserted between
the BamHI and HindIII sites of pSKS105 (M.J. Casadaban,
A. Martin-Arias, S.K. Shapira, and J. Chou, *Meth. Enzymol.*
15 100, 293 (1983)) and the LacZ portion of modified gene
was cloned into a pSV2 vector. The neomycin cassette
used for construction of pNEOβGAL was an XhoI to BamHI
fragment from pMC1neo-polyA (K. Thomas and M. Capecchi,
Cell 51:503 (1987)) cloned between copies of the J3 FRT
20 site in pUC19.
              The FRT consists of two inverted 13-base-
pair (bp) repeats and an 8-bp spacer that together
comprise the minimal FRT site, plus an additional 13-bp
repeat which may augment reactivity of the minimal
25 substrate. The β-galactosidase translational reading
frame was preserved upon insertion of the FRT site, and
the resulting plasmid, pFRTβGAL, generated robust
activity in mammalian cells (Table 1).
              pNEOβGAL was constructed by cutting
30 pFRTβGAL in the middle of the FRT site with XbaI and then
inserting an XbaI fragment consisting of two half-FRT
sites flanking a neomycin transcription unit. This
created intact FRTs on either side of the neomycin
cassette and rendered the β-galactosidase transcription
35 unit inactive (Table 1). Precise FLP-mediated
recombination of the FRTs caused the excission of the

-19-

neomycin cassette, recreated the parental pFRTβGAL
plasmid, and restored β-galactosidase expression.

Co-transfection of cells with a fixed
amount of pNEOβGAL reporter plasmid and increasing
amounts of the pOG44 FLP expression vector generated
increasing amounts of recombined reporter plasmid and
consequently, increased levels of β-galactosidase
activity. Molecular evidence for FLP-mediated
recombination was obtained by recovering plasmids 36
hours after transfection, followed by endonuclease
treatment (with EcoRI and ScaI) and Southern blotting
(see Fig. 2B; employing as a probe the fragment of
pFRTβGAL indicated at the top of Fig. 2A). Lysates of
cells from cotransfections that included the pOG44 FLP
expression vector showed a signal at 5.6 kb, the position
at which recombined reporter (equivalent to pFRTβGAL)
would run, and a 3.2 kb signal that was generated by
unrecombined pNEOβGAL reporter (Fig. 2A). The 5.6 kb
band intensity was proportional to the amount of FLP
expression plasmid included in the transfection. The 5.6
kb band was not seen in cotransfections in which a non-
FLP plasmid was substituted for the FLP expression vector
(Fig. 2B) or in transfections that contained only pOG44
(and no reporter plasmid). pOG44 generated additional
signals at 2.2 kb and 2.8 kb because the plasmid used in
its construction contained EcoRI and EcoRI-ScaI fragments
of such length.

pOG44 consists of the cytomegalovirus
immediate early promoter from pCDM8 [see Aruffo and Seed
in Proc. Natl Acad. Sci. , USA 84:8573 (1987)], a 5'
leader sequence and synthetic intron from pMLSIScat [see
Huang and Gorman in Nucl. Acids Res. 18: 937 (1990)], the
FLP coding sequence (bp 5568-6318 and 1-626 of the 2µm
circle, [see Hartley and Donelson, Nature 286: 860
(1980)] and the SV40 late region polyadenylation signal
from pMLSIScat. The following silent nucleotide

-20-

substitutions were introduced into the structural FLP
sequence using the polymerase chain reaction: C for T at
position 5791, G for A at 5794, G for C at 5800, C for T
at 55, G for A at 58, and C for T at 103. These changes

5   eliminated three cannonical AATAAA polyadenylation
signals and introduced a PstI restriction site without
altering the amino acid sequence encoded by the
nucleotide sequence. pOG28 consists of a murine cDNA for
dihydrofolate reductase cloned into pCDM8 (Aruffo and

10 Seed, supra).

In the same samples, β-galactosidase
activity was also proportional to the amount of FLP
expression plasmid included (Fig. 2C). Only background
activities were observed in cotransfections that included

15 a non-FLP control plasmid (Table 1) or when pOG44 alone
was transfected. The experiment thus provides both
molecular and biochemical evidence for precise FLP-
mediated recombination in mammalian cells.

Table 1 presents β-galactosidase

20 activities in cotransfection assays of 293, CV-1, and F-9
cells. Positive control transfections (pFRTβGAL)
included 1 μg of pFRTβGAL and 18 μg of the pOG28 non-FLP
control plasmid; negative control transfections
(pNEOβGAL) included 1 μg of pNEOβGAL and 18 μg of the

25 pOG28; and experimental transfections (pNEOβGAL + FLP)
contained 1 μg of pNEOβGAL and 18 μg of the pOG44 FLP
expression plasmid (Fig. 1A). The column headed by "%"
shows the pNEOβGAL + FLP values as a percentage of the
pFRTβGAL positive control. Each value represents the

30 mean for six plates from two experiments. Standard
errors are in parentheses. Neither pOG28 nor pOG44
generated β-galactosidase activity when transfected
alone. All transfections contained 1 μg of pRSVL [de Wet
et al., Mol. Cell. Biol. 7: 725 (1987)] to correct β-

35 galactosidase activities for relative transfection
efficiencies.

Subconfluent cultures of cells in 10 cm
dishes and grown in Dulbecco's modified Eagle's medium
(DMEM) and 5% calf serum were transfected by overnight
exposure to calcium phosphate precipitates [Graham et
al., Virology 36:59 (1979)] and then split 1:4. After 24
hours incubation, one plate of each transfection was
harvested by Hirt extraction [J. Mol Biol. 26:365 (1967)]
and a second plate was used to prepare cytoplasmic
extracts [de Wet et al., supra]. Approximately 5% of the
DNA recovered from single plates was used for Southern
analyses. β-galactosidase assays were performed as
described by Hall et al., in J. Mol. Appl. Genet. 2:101
(1983)]. Luciferase activities generated by the
inclusion of 1 μg of pRSVL (de Wet et al., supra) in all
transfections were used to correct β-galactosidase
activities for relative transfection efficiencies. The
experiment was repeated twice with similar results.

TABLE 1: β-GALACTOSIDASE ACTIVITIES (UNITS/ MG PROTEIN)
IN COTRANSFECTED CELLS

CELL LINE	TRANSFECTIONS			%
	pFRTβGAL	pNEOβGAL	pNEOβGAL + FLP	
293	30.4 (1.9)	0.17 (0.02)	14.2 (2.2)	47
CV-1	275 (25)	0.33 (0.06)	22.6 (1.2)	8
F9	24.8 (4.3)	0.04 (0.01)	1.88 (0.02)	8

FLP activity has also been demonstrated in
monkey kidney (CV-1) and mouse embryonal carcinoma (F9)
cells. In Table 1, the β-galactosidase activity in the
"pFRTβGAL" transfections represents an estimate of the
expression expected if all the pNEOβGAL in a co-

-22-

transfection were immediately recombined. The highest β-galactosidase expression in co-transfections employing pNEOβGAL plus pOG44, relative to pFRTβGAL transfected cells, was 47%, seen in 293 cells. This is a remarkable

5   level considering that β-galactosidase expression required both FLP expression, followed by recombination of pNEOβGAL, to produce a construct capable of expressing β-galactosidase. Co-transfections of CV-1 and F9 cells generated 8% of the activity seen in the pFRTβGAL

10   transfections. Even at this lower relative activity, cotransfected cells were readily observed in histochemical reactions for β-galactosidase activity.

15   Example 2
              FLP-Mediated Removal of Intervening Sequences

                    If the invention method is to be widely applicable, for example for gene activation in transgenic

20   mammals, the ability of FLP to faithfully promote precise recombination at FLP recombination target sites contained in the mammalian genome is required. Such ability is demonstrated in this example.
                    Cell lines that contain single integrated

25   copies of pNEOβGAL (designated CVNEOβGAL/E) were produced by transfecting CV-1 cells with linearized plasmid by electroporation, then isolated by selecting G418-resistant (G418^r) transfectants that stably expressed the neomycin cassette, and finally identifying single copy

30   lines by Southern blot analyses (Fig. 3). As previously shown for other integrated constructs with similarly short direct repeats, the chromosomal FRTs did not spontaneously recombine (in the absence of FLP) to produce a β-galactosidase-positive (βGAL$^-$) phenotype at

35   detectable frequencies (Table 2).

-23-

Transient expression of FLP in the
CVNEOβGAL/E lines (by transiently transfecting with the
pOG44 FLP expression vector) promoted a rapid conversion
to a βGAL⁺ phenotype. When five different lines were
5   transiently transfected with the pOG44 FLP expression
vector, β-galactosidase activities at 36 hours were 40 to
100-fold higher than those seen in replicate plates
transfected with a non-FLP plasmid (Table 2). At 48
hours after transfection histochemical processing showed
10   many positive cells (Table 2).

Table 2 presents the β-galactosidase
phenotypes of CVNEOβGAL/E lines, which contain a single
copy of the β-galactosidase inactive reporter, pNEOβGAL,
after transfection with FLP expression (pOG44), non-FLP
15   negative control (pOG28) or β-galactosidase positive
control (pFRTβGAL) plasmids. The pFRTβGAL transfections
included 1μg of pFRTβGAL and 19μg of pOG44; other mixes
contained 20μg of the indicated plasmid. β-galactosidase
activities are mean values for triplicate transfections
20   performed as described for Fig. 2 and assayed 36 hours
after removal of precipitates; standard errors for the
pOG44 transfections were less than 10% of the mean. The
percent positive was determined by scoring more than 10³
cells after transfection and histochemical processing as
25   described by de Wet et al., supra.

-24-

TABLE 2
β-GALACTOSIDASE PHENOTYPES OF
TRANSFECTED CVNEOβGAL CELL LINES

CELL LINE	ACTIVITIES (units/mg protein)		PERCENT POSITIVE		
	pOG28	pOG44	pOG28	pFRTβGAL	pOG44
E6	0.24	11.2	0†	8.7	6.1
E25	0.21	16.7	0†	17.1	12.4
E26	0.18	7.2	0†	19.5	15.4
E14	0.28	13.1	ND	ND	ND
E22	0.09	9.6	ND	ND	ND

†No positive cells were found among >10^6 cells examined.

ND: Not done.

To provide some estimate of the efficiency of recombination, an additional set of replicate plates were transfected with the pFRTβGAL β-galactosidase expression vector. Comparing the fractions of cells that were βGAL+ in the pFRTβGAL and in the pOG44 transfections (assuming similar transfection efficiencies) suggests that most (70-80%) of the cells transfected with pOG44 were converted to a βGAL⁺ phenotype (Table 2). The comparison undoubtedly underestimates the efficiency of FLP-mediated excision. Whereas many copies of a functional β-galactosidase gene were available for immediate transcription in the positive controls, recombination may have occurred shortly before harvest in some pOG44-transfected cells. In these cases the single recombined reporter gene may not have generated enough β-galactosidase by the time of harvest to render the cells positive in this assay.

-25-

    The βGAL⁺ phenotype was passed on to all
descendents of many FLP-converted cells. Positive
colonies were formed during prolonged expansion of
individual colonies. Entirely negative colonies and
5 mixed colonies were also observed. Mixed colonies would
be expected if recombination occurred after mitosis in
only one descendent of a transfected cell, or if
recombined and unrecombined cells mixed at replating or
during subsequent growth. Indeed, the physical
10 segregation of phenotypes evident in most mixed colonies
suggested that they were composed of stably positive and
negative lineages.

    The correlation between β-galactosidase
expression and recombination at FRT sites was examined by
15 comparing the structure of the integrated pNEOβGAL
sequences in two βGAL⁺ subclones to the parental line.
CVNEOβGAL/E25 (106) cells were transfected with the pOG44
FLP expression vector and subcloned 12 hours after
removal of the precipitate. After histochemical
20 screening, two βGAL⁺ subclones (E25Bl and E25B2) were
expanded for further analysis. In Southern blots of
genomic DNA from both subclones, the pattern of
hybridization matched that expected for FLP-mediated
recombination of the FRT sites in the parental line (Fig.
25 3). While recombination products have not been recovered
and sequenced, these Southern analyses and the fact that
activation of β-galactosidase expression required
creation of a functional translational reading frame
indicate that FLP-mediated recombination was precise.

30

Example 3

FLP Mediated Recombination of FRT

on an Extrachromosomal Molecule With a

Chromosomally Integrated FRT

5

Reversal of the process described in the
previous Example, i.e., the FLP-mediated recombination of
an FRT site on a plasmid with a chromosomally integrated
FRT site, can be used to target the integration of
10 transfected plasmids to specific genomic sites. To
determine the frequency at which this occurs, G418-
sensitive, βGAL[-] E25B2 cells were co-transfected with the
pOG44 FLP expression vector and a plasmid, pOG45, that
contained a neomycin resistance gene expression cassette
15 and a single FRT. pOG45 consisted of the neomycin
resistance cassette and 3' FRT from pNEOβGAL cloned into
pUC19. 8×10^5 CVNEOβGAL cells were transfected by
electroporation in 800 μl of saline containing 40 μg of
pOG44 and 0.1 μg of either pOG45 or, for a negative
20 control, pOG45A (which was derived from pOG45 by deleting
a 200 bp fragment containing the FRT).

G418[R] subclones (designated B2N) from three
transfections that had stably integrated pOG45 were
histochemically stained for β-galactosidase activity and
25 more than half (104 of 158, or ~66%) were either entirely
β-galactosidase-negative (βGAL[-]) or predominantly βGAL[-]
with a few clusters of βGAL[+] cells. The remaining
colonies were βGAL[+]. With continued passage as dispersed
monolayers, the fraction of βGAL[+] cells in the mosaic
30 lines rapidly diminished. This suggested they were G418[-]
sensitive cells that initially survived because of their
proximity to resistant cells; this was confirmed by
reconstitution experiments. All of the 55 colonies
formed after parallel co-transfections of pOG44 and a
35 derivative of pOG45 (pOG45A) that lacked an FRT were
βGAL[+].

-27-

        The correlation between loss of
β-galactosidase activity and recombination between
plasmid and chromosomal FRTs was examined in Southern
analyses. Because the FRT and neomycin cassette of pOG45
5   were derived from the neomycin cassette and 3' FRT of
pNEOβGAL (Fig. 2A), recombination of the plasmid FRT with
the E25B2 chromosomal FRT regenerates the 3.2 kb EcoRI
fragment of the original CVNEOβGAL/E25 parent.
Additionally, the 8.5 kb junctional fragment of
10 CVNEOβGAL/E25 shifts to 12.0 kb because pOG45 is 3.5 kb
larger than the neomycin cassette of pNEOβGAL. The 3.2
kb EcoRI fragment and the 8.5 kb junctional fragment were
observed in each of the 10 cell lines analyzed after
initial histochemical classification as βGAL⁻ or mosaic,
15 as shown for two such lines in Fig. 3B. In contrast,
each of the four βGAL+ colonies examined by Southern
analyses showed that pOG45 had integrated at a random
site.

        These data show that FLP-mediated
20 recombination will target the integration of transfected
DNA to a specific chromosomal site at frequencies that
exceed those of random integration, and that the event
can be marked by the alteration in gene activity at the
target site. The efficiency of targeted integration can
25 be increased by standard optimization techniques, such as
for example, by using ratios of the integrating plasmid
and FLP expression vectors different from the single
ratio mixture used here, or by using FRT mutations in the
plasmid and chromosomal sites to decrease the frequency
30 with which successfully integrated plasmids are
subsequently excised.

        While the invention has been described in
detail with reference to certain preferred embodiments
thereof, it will be understood that modifications and
35 variations are within the spirit and scope of that which
is described and claimed.

-28-

SUMMARY OF SEQUENCES

Sequence I.D. No. 1 is the approximately
1450 base-pair sequence encoding a FLP recombinase
5   contemplated for use in the practice of the present
invention, as well as the amino acid sequence deduced
therefrom.

Sequence I.D. No. 2 is the amino acid
sequence deduced from the nucleotide sequence of Sequence
10   ID No. 1.

-29-

SEQUENCE LISTING

(1) GENERAL INFORMATION:

   (i) APPLICANT: WAHL, DR, GEOFFREY M
              O'GORMAN DR, STEPHEN V

   (ii) TITLE OF INVENTION: FLP-MEDIATED GENE MODIFICATION IN
           MAMMALIAN CELLS, AND COMPOSITIONS AND CELLS USEFUL
           THEREFOR

   (iii) NUMBER OF SEQUENCES: 2

   (iv) CORRESPONDENCE ADDRESS:
       (A) ADDRESSEE: FITCH, EVEN, TABIN & FLANNERY
       (B) STREET: 135 South LaSalle Street, Suite 510
       (C) CITY: Chicago
       (D) STATE: Illinois
       (E) COUNTRY: USA
       (F) ZIP: 60603

   (v) COMPUTER READABLE FORM:
       (A) MEDIUM TYPE: Floppy disk
       (B) COMPUTER: IBM PC compatible
       (C) OPERATING SYSTEM: PC-DOS/MS-DOS
       (D) SOFTWARE: PatentIn Release #1.0, Version #1.25

   (vi) CURRENT APPLICATION DATA:
       (A) APPLICATION NUMBER: US
       (B) FILING DATE:
       (C) CLASSIFICATION:

   (viii) ATTORNEY/AGENT INFORMATION:
       (A) NAME: REITER MR, STEPHEN E
       (B) REGISTRATION NUMBER: 31192
       (C) REFERENCE/DOCKET NUMBER: 50730

   (ix) TELECOMMUNICATION INFORMATION:
       (A) TELEPHONE: (619) 552-1311
       (B) TELEFAX: (619) 552-0095
       (C) TELEX: 20 6566 PATLAW CGO

-30-

(2) INFORMATION FOR SEQ ID NO:1:

    (i) SEQUENCE CHARACTERISTICS:
        (A) LENGTH: 1380 base pairs
        (B) TYPE: nucleic acid
        (C) STRANDEDNESS: single
        (D) TOPOLOGY: linear

    (ii) MOLECULE TYPE: DNA (genomic)

    (vii) IMMEDIATE SOURCE:
        (B) CLONE: NATIVE FLP

    (ix) FEATURE:
        (A) NAME/KEY: CDS
        (B) LOCATION: 1..1269

    (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

```
ATG CCA CAA TTT GAT ATA TTA TGT AAA ACA CCA CCT AAG GTG CTT GTT        48
Met Pro Gln Phe Asp Ile Leu Cys Lys Thr Pro Pro Lys Val Leu Val
1               5                  10                  15

CGT CAG TTT GTG GAA AGG TTT GAA AGA CCT TCA CGT GAG AAA ATA GCA        96
Arg Gln Phe Val Glu Arg Phe Glu Arg Pro Ser Gly Glu Lys Ile Ala
            20                  25                  30

TTA TGT GCT GGT GAA CTA ACG TAT TTA TGT TCG ATG ATT ACA CAT AAG       144
Leu Cys Ala Ala Glu Leu Thr Tyr Leu Cys Trp Met Ile Thr His Asn
        35                  40                  45

GGA ACA GCA ATG AAG AGA GCC ACA TTC ATG AGC TAT AAT ACT ATC ATA       192
Gly Thr Ala Ile Lys Arg Ala Thr Phe Met Ser Tyr Asn Thr Ile Ile
    50                  55                  60

AGC AAT TCG CTG AGT TTC GAT ATT GTC AAT AAA TCA CTC CAG TTT AAA       240
Ser Asn Ser Leu Ser Phe Asp Ile Val Asn Lys Ser Leu Gln Phe Lys
65                  70                  75                  80

TAC AAG ACG CAA AAA CCA ACA ATT CTG GAA CCC TCA TTA AAG AAA TTG       288
Tyr Lys Thr Gln Lys Ala Thr Ile Leu Glu Ala Ser Leu Lys Lys Leu
                85                  90                  95

ATT CCT GGT TGG GAA TTT ACA ATT ATT CCT TAC TAT GGA CAA AAA CAT       336
Ile Pro Gly Trp Glu Phe Thr Ile Ile Pro Tyr Tyr Gly Gln Lys His
            100                 105                 110

CAA TCT GAT ATG ACT GAT ATT GTA AGT AGT TTG CAA TTA CAG TTC GAA       384
Gln Ser Asp Ile Thr Asp Ile Val Ser Ser Leu Gln Leu Gln Phe Glu
        115                 120                 125

TCA TCG GAA GAA GCA GAT AAG GGA AAT GAC CAC AGT AAA AAA ATG CTT       432
Ser Ser Glu Glu Ala Asp Lys Gly Asn Asp His Ser Lys Lys Met Leu
    130                 135                 140

AAA GCA CTT CTA AGT GAG GGT GAA AGC ATC TGG GAG ATC ACT GAG AAA       480
Lys Ala Leu Leu Ser Glu Gly Glu Ser Ile Trp Glu Ile Thr Glu Lys
145                 150                 155                 160
```

-31-

```
ATA CTA AAT TCG TTT GAG TAT ACT TCG AGA TTT ACA AAA ACA AAA ACT          528
Ile Leu Asn Ser Phe Glu Tyr Thr Ser Arg Phe Thr Lys Thr Lys Thr
                          165                 170                 175

TTA TAC CAA TTC CTC TTC CTA GCT ACT TTC ATC AAT TGT GGA AGA TTC          576
Leu Tyr Gln Phe Leu Phe Leu Ala Thr Phe Ile Asn Cys Gly Arg Phe
                  180                 185                 190

AGC GAT ATT AAG AAC GTT GAT GCG AAA TCA TTT AAA TTA GTC CAA AAT          624
Ser Asp Ile Lys Asn Val Asp Ala Lys Ser Phe Lys Leu Val Gln Asn
              195                 200                 205

AAG TAT CTG GGA GTA ATA ATA CAG TGT TTA GTG ACA GAG ACA AAG ACA          672
Lys Tyr Leu Gly Val Ile Ile Gln Cys Leu Val Thr Glu Thr Lys Thr
          210                 215                 220

AGC GTT AGT AGG CAC ATA TAC TTC TTT AGC GCA AGG GGT AGG ATC GAT          720
Ser Val Ser Arg His Ile Tyr Phe Phe Ser Ala Arg Gly Arg Ile Asp
225                 230                 235                 240

CCA CTT GTA TAT TTG GAT GAA TTT TTG AGG AAT TCT GAA CCA GTC CTA          768
Pro Leu Val Tyr Leu Asp Glu Phe Leu Arg Asn Ser Glu Pro Val Leu
                          245                 250                 255

AAA CGA GTA AAT AGG ACC GGC AAT TCT TCA AGC AAT AAA CAG GAA TAC          816
Lys Arg Val Asn Arg Thr Gly Asn Ser Ser Ser Asn Lys Gln Glu Tyr
                  260                 265                 270

CAA TTA TTA AAA GAT AAC TTA GTC AGA TCG TAC AAT AAA GCT TTG AAG          864
Gln Leu Leu Lys Asp Asn Leu Val Arg Ser Tyr Asn Lys Ala Leu Lys
              275                 280                 285

AAA AAT GCG CCT TAT TCA ATC TTT GGT ATA AAA AAT GGC CCA AAA TCT          912
Lys Asn Ala Pro Tyr Ser Ile Phe Gly Ile Lys Asn Gly Pro Lys Ser
          290                 295                 300

CAC ATT GGA AGA CAT TTG ATG AGC TCA TTT GTT TCA ATG AAG GGC CTA          960
His Ile Gly Arg His Leu Met Ser Ser Phe Val Ser Met Lys Gly Leu
305                 310                 315                 320

ACG GAG TTG AGT AGT GTT GTG GGA AAT TGG AGC GAT AAG CGT GCT TCT         1008
Thr Glu Leu Ser Ser Val Val Gly Asn Trp Ser Asp Lys Arg Ala Ser
                          325                 330                 335

GCC GTG GCC ACG ACA ACG TAT ACT CAT CGA ATA ACA GCA ATA CCT GAT         1056
Ala Val Ala Arg Thr Thr Tyr Thr His Gln Ile Thr Ala Ile Pro Asp
                  340                 345                 350

CAC TAC TTC GCA CTA GTT TCT CGG TAC TAT GCA TAT GAT CCA ATA TCA         1104
His Tyr Phe Ala Leu Val Ser Arg Tyr Tyr Ala Tyr Asp Pro Ile Ser
          355                 360                 365

AAG GAA ATG ATA GCA TTG AAG GAT GAG ACT AAT CCA ATT CAG GAG TGG         1152
Lys Glu Met Ile Ala Leu Lys Asp Glu Thr Asn Pro Ile Glu Glu Trp
          370                 375                 380

CAG CAT ATA GAA GGA CTA AAG GGT AGT GCT GAA GGA AGC ATA CGA TAC         1200
Gln His Ile Glu Gly Leu Lys Gly Ser Ala Glu Gly Ser Ile Arg Tyr
385                 390                 395                 400
```

-32-

```
CCC GCA TGG AAT GGG ATA ATA TCA CAG GAG GTA CTA GAC TAC CTT TCA    1248
Pro Ala Trp Asn Gly Ile Ile Ser Gln Glu Val Leu Asp Tyr Leu Ser
            405               410               415

TCG TAC ATA AAT AGA CGC ATA TAAGTACGCA TTTAAGCATA AACACGCACT       1299
Ser Tyr Ile Asn Arg Arg Ile
        420

ATGCCGTTCT TCTCATGTAT ATATATATAC AGGCAACACG CAGATATAGG TGCGACGTGA   1359

ACAGTGAGCT GTATGTGCGC A                                            1380
```

(2) INFORMATION FOR SEQ ID NO:2:

    (i) SEQUENCE CHARACTERISTICS:
        (A) LENGTH: 423 amino acids
        (B) TYPE: amino acid
        (D) TOPOLOGY: linear

    (ii) MOLECULE TYPE: protein

    (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

```
Met Pro Gln Phe Asp Ile Leu Cys Lys Thr Pro Pro Lys Val Leu Val
1               5               10              15

Arg Gln Phe Val Glu Arg Phe Glu Arg Pro Ser Gly Glu Lys Ile Ala
            20              25              30

Leu Cys Ala Ala Glu Leu Thr Tyr Leu Cys Trp Met Ile Thr His Asn
            35              40              45

Gly Thr Ala Ile Lys Arg Ala Thr Phe Met Ser Tyr Asn Thr Ile Ile
        50              55              60

Ser Asn Ser Leu Ser Phe Asp Ile Val Asn Lys Ser Leu Gln Phe Lys
65              70              75              80

Tyr Lys Thr Gln Lys Ala Thr Ile Leu Gln Ala Ser Leu Lys Lys Leu
            85              90              95

Ile Pro Ala Trp Glu Phe Thr Ile Ile Pro Tyr Tyr Gly Gln Lys His
            100             105             110

Gln Ser Asp Ile Thr Asp Ile Val Ser Ser Leu Gln Leu Gln Phe Glu
        115             120             125

Ser Ser Glu Glu Ala Asp Lys Gly Asn Ser His Ser Lys Lys Met Leu
    130             135             140

Lys Ala Leu Leu Ser Glu Gly Glu Ser Ile Trp Glu Ile Thr Glu Lys
145             150             155             160

Ile Leu Asn Ser Phe Glu Tyr Thr Ser Arg Phe Thr Lys Thr Lys Thr
            165             170             175

Leu Tyr Gln Phe Leu Phe Leu Ala Thr Phe Ile Asn Cys Gly Arg Phe
        180             185             190
```

-33-

Ser Asp Ile Lys Asn Val Asp Pro Lys Ser Phe Lys Leu Val Gln Asn
        195   200   205

Lys Tyr Leu Gly Val Ile Ile Gln Cys Leu Val Thr Glu Thr Lys Thr
    210   215   220

Ser Val Ser Arg His Ile Tyr Phe Phe Ser Ala Arg Gly Arg Ile Asp
225   230   235   240

Pro Leu Val Tyr Leu Asp Glu Phe Leu Arg Asn Ser Glu Pro Val Leu
                245   250   255

Lys Arg Val Asn Arg Thr Gly Asn Ser Ser Ser Asn Lys Gln Glu Tyr
        260   265   270

Gln Leu Leu Lys Asp Asn Leu Arg Ser Tyr Asn Lys Ala Leu Lys
        275   280   285

Lys Asn Ala Pro Tyr Ser Ile Phe Ala Ile Lys Asn Gly Pro Lys Ser
        290   295   300

His Ile Gly Arg His Leu Met Thr Ser Phe Leu Ser Met Lys Gly Leu
305   310   315   320

Thr Glu Leu Thr Asn Val Val Gly Asn Trp Ser Asp Lys Arg Ala Ser
                325   330   335

Ala Val Ala Arg Thr Thr Tyr Thr His Gln Ile Thr Ala Ile Pro Asp
            340   345   350

His Tyr Phe Ala Leu Val Ser Arg Tyr Tyr Ala Tyr Asp Pro Ile Ser
        355   360   365

Lys Glu Met Ile Ala Leu Lys Asp Glu Thr Asn Pro Ile Glu Glu Trp
    370   375   380

Gln His Ile Glu Gln Leu Lys Gly Ser Ala Glu Gly Ser Ile Arg Tyr
385   390   395   400

Pro Ala Trp Asn Gly Ile Ile Ser Gln Glu Val Leu Asp Tyr Leu Ser
                405   410   415

Ser Tyr Ile Asn Arg Arg Ile
            420

THAT WHICH IS CLAIMED IS:

       1. A mammalian recombination system comprising:

5   (i) FLP recombinase, or a nucleotide sequence encoding same, and

         (ii) a first DNA comprising a nucleotide sequence containing at least one FLP recombination target site therein.

10

       2. A recombination system according to Claim 1 further comprising:

         (iii)   a second DNA, wherein said second DNA is selected from:

15   (a) at least a second portion of said first gene of interest, or

           (b) at least a portion of a second gene of interest;

wherein said second DNA contains at least one FLP
20 recombination target site; and wherein said second DNA, when combined in reading frame with said first DNA, provides a functional gene.

       3. A recombination system according to Claim 2
25 wherein said second DNA comprises an additional portion of said first gene of interest.

       4. A recombination system according to Claim 2 wherein said second DNA comprises at least a portion of a
30 second gene of interest.

       5. A recombination system according to Claim 4 wherein said portion of said second gene of interest,

-35-

when combined in reading frame with said first DNA,
provides a hybrid, functional gene.

6. A recombination system according to Claim 4
wherein said portion of said second gene of interest,
when combined with said first DNA, disrupts the function
of said first gene of interest.

7. A recombination system according to Claim 1
wherein said first DNA further comprises a second FLP
recombination target site.

8. A recombination system according to Claim 1
wherein the FLP recombinase is derived from a species of
the genus Saccharomyces.

9. A recombination system according to Claim 1
wherein the FLP recombinase is derived from a strain of
Saccharomyces cerevisiae.

10. A recombination system according to Claim 9
wherein said FLP recombinase is encoded by the
approximately 1450 base pair sequence set forth as
Sequence ID No. 1.

11. A recombination system according to Claim 1
wherein said first DNA provides a readily analyzable
marker feature to the host system.

12. A recombination system according to Claim 2
wherein said second DNA provides a readily analyzable
marker feature to the host system.

-36-

13. A DNA construct comprising, as an autonomous fragment:

    (a)   at least one FLP recombination target site,

    (b)   at least one restriction endonuclease recognition site,

    (c)   at least one marker gene,

    (d)   a bacterial origin of replication, and optionally

    (e)   a mammalian cellular or viral origin of DNA replication.

14. A DNA construct comprising, as an autonomous fragment, in the following order, reading from 5' to 3' along said fragment:

    (a)   a first FLP recombination target site,

    (b)   an insert portion comprising, in any suitable sequence:

        (1)   at least one restriction endonuclease recognition site,

        (2)   at least one marker gene,

        (3)   a bacterial origin of replication, and optionally

        (4)   a mammalian cellular or viral origin of DNA replication, and

    (c)   a second FLP recombination target site in tandem with said first FLP recombination target site.

15. A method for the assembly of functional gene(s), which is (are) then suitable for activation of expression in mammalian cells, by recombination of individually inactive gene segments derived from one or

-37-

more gene(s) of interest, wherein each of said segments
contains at least one recombination target site, said
method comprising:

5
        contacting said individually inactive gene
        segments with a FLP recombinase, under
        conditions suitable for recombination to occur,
        thereby providing a DNA sequence which encodes
        a functional gene of interest.

10
        16. A method according to Claim 15 wherein the
FLP recombinase is derived from a species of the genus
Saccharomyces.

        17. A method according to Claim 15 wherein the
15
FLP recombinase is derived from a strain of Saccharomyces
cerevisiae.

        18. A method according to Claim 17 wherein said
FLP recombinase is encoded by the approximately 1450 base
20
pair sequence set forth as Sequence ID No. 1.

        19. A method for the disruption of functional
gene(s) of interest, rendering said gene(s) unable to be
inactivated for expression in mammalian cells wherein
25
said gene(s) of interest contain at least one FLP
recombination target site, said method comprising
contacting said gene(s) of interest with:

        (i) a DNA segment which contains at least one
            FLP recombination target site, and
30
        (ii) FLP recombinase;
wherein said contacting is carried out under conditions
suitable for recombination to occur between said gene and

-38-

said DNA segment, thereby disrupting the gene(s) of
interest and rendering said gene(s) non-functional.

20. A method according to Claim 19 wherein said
DNA segment provides a readily analyzable marker feature
to the host system.

21. A method according to Claim 19 wherein the
FLP recombinase is derived from a species of the genus
Saccharomyces.

22. A method according to Claim 19 wherein the
FLP recombinase is derived from a strain of Saccharomyces
cerevisiae.

23. A method according to Claim 22 wherein said
FLP recombinase is encoded by the approximately 1450 base
pair sequence set forth as Sequence ID No. 1.

24. A method for the recovery of transfected
DNA from the genome of a transfected organism, wherein
the genomic DNA of said transfected organism contains a
fragment having two tandemly oriented FLP recombination
target sites therein, said method comprising contacting
genomic DNA from said organism with FLP.

25. A method for the precisely targeted
integration of DNA into the genome of a host organism,
said method comprising:
          (i)   introducing a FLP recombination target
                 site into the genome of cells which are
                 compatible with the cells of the subject,

-39-

   (ii) introducing a first DNA comprising a
       nucleotide sequence containing at least
       one FLP recombination target site therein
       into the FLP recombination target site in
5   the genome of said cells by contacting
       said cells with said first DNA and FLP
       recombinase, and thereafter
   (iii) introducing the cells produced by the
       process of step (ii) into said subject.

10

    26. A method according to Claim 25, further
comprising contacting the genomic DNA from said subject
with FLP, thereby recovering the transfected DNA
containing said first gene of interest from the genome of
15 said transfected organism.

    27. A method according to Claim 26, further
comprising introducing at least a portion of a second
gene of interest into said FLP recombination target site.
20

    28. A method according to Claim 25, further
comprising introducing at least a portion of a second
gene of interest into one of the FLP recombination target
sites of said subject.

25

    29. A mammalian cell, wherein the genomic DNA
of said cell contains at least one FLP recombination
target site therein.

30   30. A mammalian cell according to Claim 29
wherein said FLP recombination target site in the genomic
DNA of said cell is positioned within at least a portion
of one or more gene(s) of interest.

-40-

31. A mammalian cell according to Claim 30, further comprising DNA encoding, and capable of expressing, in mammalian cells, a FLP recombinase.

5   32. A mammalian cell according to Claim 30 wherein said gene(s) of interest provide a readily analyzable marker feature to the host system.

33. A mammalian cell according to Claim 29
10   wherein said FLP recombination target site has the sequence:

5'-GAAGTTCCTATTCTCTAGAAAGTATAGGAACTT,

15   or functional equivalents thereof.

34. A mammalian cell according to Claim 30 further comprising an additional DNA fragment, wherein said additional DNA fragment is selected from:
20   (a)   at least a second portion of said first gene of interest, or
                (b)   at least a portion of a second gene of interest;
     wherein said second DNA contains at least one FLP
25   recombination target site; and wherein said second DNA, when combined in reading frame with said first DNA, provides a functional gene.

35. A transgenic, non-human mammal, wherein
30   said mammal contains at least one FLP recombination target site in the genomic DNA thereof.

36. A transgenic, non-human mammal according to
Claim 35 wherein said FLP recombination target site is
positioned within at least a portion of one or more
gene(s) of interest.

5

37. A transgenic, non-human mammal according to
Claim 35, further comprising a nucleotide sequence
encoding, and capable of expressing, in transgenic, non-
human mammals, a FLP recombinase.

10

38. A transgenic, non-human mammal according to
Claim 35, further comprising FLP recombinase.

39. A transgenic, non-human mammal according to
15 Claim 36 wherein said gene(s) of interest provide a
readily analyzable marker feature to the host system.

40. A transgenic, non-human mammal according to
Claim 35 wherein said FLP recombination target site has
20 the sequence:

5'-GAAGTTCCTATTCTCTAGAAAGTATAGGAACTT,

or functional equivalents thereof.

25

41. A transgenic, non-human mammal according to
Claim 36 further comprising an additional DNA fragment,
wherein said additional DNA fragment is selected from:
(a) at least a second portion of said
30   first gene of interest, or
(b) at least a portion of a second gene
of interest;
wherein said second DNA contains at least one FLP
recombination target site; and wherein said second DNA,
35 when combined in reading frame with said first DNA,
provides a functional gene.

-42-

42. A method for the site-specific integration of transfected DNA into the genome of a cell according to Claim 29, said method comprising:

    (i)   contacting said genome with:

       (a) FLP recombinase, and

       (b) a first DNA comprising at least a portion of a first gene of interest;

         wherein said first DNA contains at least one FLP recombination target site; and thereafter

    (ii) maintaining the product of step (i) under conditions suitable for site-specific integration of said DNA sequence to occur at the FLP recombination target site in said genome of the host cells.

43. A method according to Claim 42 wherein said FLP recombination target site in the genomic DNA of said cell is positioned within at least a portion of one or more gene(s) of interest.

44. A method according to Claim 42 further comprising additionally contacting said host cell with a second DNA, wherein said second DNA is selected from:

       (a) at least a second portion of said first gene of interest, or

       (b) at least a portion of a second gene of interest;

wherein said second DNA contains at least one FLP recombination target site; and wherein said second DNA, when combined in reading frame with said first DNA, provides a functional gene.

45. A method according to Claim 42 wherein said FLP recombinase is provided by a FLP expression vector.

46. A method according to Claim 45 wherein the expression of FLP recombinase by said FLP expression vector is subject to regulatory control.

5   47. A method according to Claim 42 wherein said FLP recombination target site is introduced into the genome of said host mammalian cell by transfecting said host cell with a DNA fragment containing at least one recombination target site therein.

10

48. A method according to Claim 42 wherein the FLP recombination target site in the genomic DNA of said host mammalian cell is so positioned that the introduction of additional DNA sequences therein will 15 inactivate the target gene.

49. A method for the site-specific integration of transfected DNA into the genome of a host according to Claim 35, said method comprising:

20   (i)   contacting said genome with:
              (a)   FLP recombinase, and
              (b)   a first DNA comprising a nucleotide
                    sequence containing at least one FLP
                    recombination target site therein;
25   and thereafter
       (ii) maintaining the product of step (i) under
              conditions suitable for site-specific
              integration of said DNA sequence to occur
              at the FLP recombination target site in
30   said genome of the host.

50. A method according to Claim 49 wherein said FLP recombination target site is positioned within at least a portion of one or more gene(s) of interest.

35

-44-

51. A method according to Claim 49 further
comprising additionally contacting said host with a
second DNA, wherein said second DNA is selected from:

  (a) at least a second portion of said
5 first gene of interest, or

   (b) at least a portion of a second gene
  of interest;

wherein said second DNA contains at least one FLP
recombination target site; and wherein said second DNA,
10 when combined in reading frame with said first DNA,
provides a functional gene.

52. A method according to Claim 49 wherein said
FLP recombinase is provided by a FLP expression vector.

15

53. A method according to Claim 52 wherein the
expression of FLP recombinase by said FLP expression
vector is subject to regulatory control.

20 54. A method according to Claim 49 wherein said
FLP recombination target site is introduced into the
genome of said host mammal by transfecting said host with
a DNA fragment containing at least one recombination
target site therein.

25

55. A method according to Claim 49 wherein the
DNA of said host mammal contains at least one FLP
recombination target site, and wherein said FLP
recombination target site is so positioned that the
30 introduction of additional DNA sequences therein will
inactivate the target gene.

56. A method for the analysis of the
development of a mammal, said method comprising:

    (a) providing a transgenic mammal comprising:

        (i)   an expression construct encoding FLP
5   under the control of a conditional
               promoter, and

        (ii)   a reporter construct under the
               control of the same or a different
               promoter, wherein said reporter
10   construct encodes a functional or
               non-functional reporter gene
               product, and wherein said construct
               contains at least one FLP
               recombination target site therein,
15   wherein the functional
               expression of the functional
               reporter gene is disrupted when said
               FLP recombination event occurs, or
                  wherein the functional
20   expression of the non-functional
               reporter gene commences when said
               FLP recombination event occurs; and

    (b) following the development of said mammal to
determine when expression of functional reporter gene
25 product either commences or is disrupted.

57. A method according to Claim 56 wherein said
conditional promoter is developmentally-regulated.

30   58. A co-transfection assay for the occurrence
of FLP-mediated recombination, said assay comprising:

    (a) co-transfecting a host mammalian cell
with:

35   (i) a FLP expression plasmid, and
        (ii) a reporter plasmid comprising a non-
           functional reporter gene wherein said non-
           functional reporter gene is inactivated by

-46-

the presence of extraneous DNA containing
at least one recombination target site;
and

(b)   monitoring said host cell under a variety
5   of conditions for the gain of expression of functional
reporter gene product.

59.   A co-transfection assay for the occurrence
of FLP-mediated recombination, said assay comprising:
10   (a)   co-transfecting a host mammalian cell
with:

(i)   a FLP expression plasmid, and
(ii) a reporter plasmid comprising a
functional reporter gene containing at
15   least one recombination target site
therein; and

(b)   monitoring said host cell under a variety
of conditions for the loss of expression of functional
reporter gene product.

20

FIG.1A

FIG.1B

SUBSTITUTE SHEET

FIG.2A

pFRTβGAL

pNEOβGAL

pOG44 FLP

FIG.2B

FIG.2C

FIG.3B

FIG.3A

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US92/01899

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all)[3]

According to International Patent Classification (IPC) or to both National Classification and IPC

IPC (5): C12N 15/15, 5/16; CO7H 15/12
US CL : 435/320.1, 240.2, 172.3; 536/27

II. FIELDS SEARCHED

Minimum Documentation Searched[4]	
Classification System	Classification Symbols
U.S.	435/320.1, 240.2, 172.3; 536/27

Documentation Searched other than Minimum Documentation to the extent that such Documents are included in the Fields Searched[5]
Please See Attached Sheet.

III. DOCUMENTS CONSIDERED TO BE RELEVANT[14]

Category*	Citation of Document,[16] with indication, where appropriate, of the relevant passages[17]	Relevant to Claim No.[18]
Y	Cell, volume 59, issued 03 November 1989, Golic et al., "The FLP Recombinase Of Yeast Catalyzes Site-Specific Recombination In The Drosophila Genome", pages 499-509. See entire document.	1-18, 29-34
Y	Cell, volume 21, issued September 1980, Broach et al., "Replication And Recombination Functions Associated With The Yeast Plasmid, 2μ Circle", pages 501-508. See entire document.	1-18, 29-34
Y	Proc. Natl. Acad. Sci. USA, volume 82, issued September 1985, Jayaram, "Two-Micrometer Circle Site-Specific Recombination: The Minimal Substrate And The Possible Role Of Flanking Sequences", pages 5875-5879. See entire document.	1-18, 29-34
Y	J. Bacteriol., volume 169, no. 12, issued December 1987, Utatsu et al., "Yeast Plasmids Resembling 2μm DNA: Regional Similarities And Diversities At The Molecular Level", pages 5537-5545. See entire document.	1-18, 29-34

* Special categories of cited documents:[16]
"A" document defining the general state of the art which is not considered to be of particular relevance
"E" earlier document but published on or after the international filing date
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O" document referring to an oral disclosure, use, exhibition or other means
"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step
"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"&" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search[2]	Date of Mailing of this International Search Report[2]
06 JUNE 1992	24 JUN 1992
International Searching Authority[1]	Signature of Authorized Officer[20]
ISA/US	Debora Frese (signature) CHRISTOPHER S. F. LOW

Form PCT/ISA/210 (second sheet)(May 1988) 8

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

Y	Molec. Cell. Biol., volume 7, no. 6, issued June 1987, Sauer, "Functional Expression Of The cre-lox Site-Specific Recombination System In The Yeast Saccharomyces cerevisiae, pages 2087-2096. See entire document.	1-18, 29-34
Y	J. Molec. Biol., volume 201, issued 1988, Senecoff et al., "DNA Recognition By The FLP Recombinase Of The Yeast 2µ Plasmid. A Mutational Analysis Of The FLP Binding Site", pages 405-421. See entire document.	1-18, 29-34
Y	US, A, 4,959,317 (Sauer) issued 25 September 1990. See at least col 14.	1-18, 29-34

V. ☐ **OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE[1]**

1. ☐ Claim numbers _, because they relate to subject matter (1) not required to be searched by this Authority, namely:

2. ☐ Claim numbers _, because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out (1), specifically:

3. ☐ Claim numbers _, because they are dependent claims not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☒ **OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING[2]**

This International Searching Authority found multiple inventions in this international application as follows:

Please See Attached Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.

2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:

3. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:

   1-18 and 29-34
   (Telephone Practice)

4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Search Authority did not invite payment of any additional fee.

Remark on protest

   ☐ The additional search fees were accompanied by applicant's protest.
   ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PREVIOUS SHEETS

II. FIELDS SEARCHED
Other Documents Searched:

APS: USPAT and JPOABS
DIALOG: BIOSIS, MEDLINE, CA SEARCH, SCISEARCH, LIFE SCIENCES COLLECTION, PASCAL,
CONFERENCE PAPERS INDEX, WORLD PATENTS INDEX

SEARCH TERMS: FLP recombinas?

VI. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING
This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which
are not so linked so as to form single inventive concept and does not meet the
criteria of PCT Rule 13.1 and 13.2. The sequential Roman numerals identify the
groups.

   I.   Claims 1-18 and 29-34, drawn to a mammalian recombination
             system, DNA, transformed host cells, and method of
             assembling functional genes are classified in Class 435,
             subclasses 320.1, 240.2, 172.3 and Class 536, subclass 27.

   II.   Claims 19-23, drawn to a method of disrupting gene
             function are classified in Class 435, subclass 172.3.

   III.   Claim 24, drawn to a method of recovering DNA is
             classified in Class 435, subclass 91.

   IV.   Claims 25-28 and 42-55, drawn to methods of targeted (site
             specific) DNA integration contain species drawn to cells
             per se (claims 25-28 and 42-48) and claims drawn to non-
             human transgenic animals (claims 25-28 and 49-55) are
             classified in Class 435, subclasses 172.1, 172.3, 240.2
             and in Class 800 subclass 2.

   V.   Claims 35-41, drawn to non-human transgenic animals are
             classified in Class 800, subclass 2.

   VI.   Claims 56 and 57, drawn to a method for analysis of
             mammalian development are classified in Class 435,
             subclass 4.

   VII.   Claims 58 and 59, drawn to a cotransfection assay are
             classified in Class 435, subclass 6.

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category*	Citation of Document,[16] with indication, where appropriate, of the relevant passages[17]	Relevant to Claim No.[18]
Y	Proc. Natl. Acad. Sci. USA, volume 85, issued July 1988, Sauer et al., "Site-Specific DNA Recombination In Mammalian Cells By The Cre Recombinase Of Bacteriophage P1", pages 5166-5170.	1-18, 29-34
Y	Nucleic Acids Research, volume 17, no. 1, issued 11 January 1989, Sauer et al., "Cre-Stimulated Recombination At loxP-Containing DNA Sequences Placed Into The Mammalian Genome", pages 147-161. See entire document.	1-18, 29-34
Y	The New Biologist, volume 2, no. 5, issued May 1990, Sauer et al., "Targeted Insertion Of Exogenous DNA Into The Eukaryotic Genome By The Cre Recombinase", pages 441-449. See entire document.	1-18, 29-34
Y	US, A, 4,997,757 (Schiestl) issued 05 March 1991. See entire document.	1-18, 29-34
A,X	Science, volume 251, issued 15 March 1991, O'Gorman et al., "Recombinase-Mediated Gene Activation and Site-Specific Integration In Mammalian Cells", pages 1351-1355. See entire document.	1-18, 29-34